MEB-1170
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MEB-1170 is an atypical opioid receptor modulator which is under development for the treatment of pain and opioid use disorder.[1][2][3][4][5] It is a highly biased agonist of the μ-opioid receptor (MOR)[3] and appears to be biased for activation of G protein signaling over β-arrestin recruitment.[6] Aside from the fact that it is a MOR biased agonist, the drug is said to be a MOR full agonist as well as a κ-opioid receptor (KOR) partial agonist and to have a unique pharmacological profile.[5] It is taken orally.[1]
- None
| Clinical data | |
|---|---|
| Other names | MEB1170 |
| Routes of administration | Oral[1] |
| Drug class | μ-Opioid receptor biased agonist; κ-Opioid receptor agonist; Analgesic; Opioid replacement |
| ATC code |
|
The drug produces robust analgesia in several assays similarly to morphine in rodents.[3][4][6][5][7] However, in contrast to other MOR agonists like morphine and oliceridine, MEB-1170 is said to have not produced analgesic tolerance, sedation, respiratory depression, rewarding effects, or reinforcing effects and to have shown only minimal withdrawal symptoms.[3][4][6][5][7] In addition, unlike morphine, but similarly to oliceridine, it negligibly affected gastrointestinal transit, a measure of constipation-like effect.[3][4][6] As such, the drug is claimed to have greatly improved tolerability, safety, and misuse liability relative to conventional opioids like morphine.[3][4][6][5] The toxicokinetics of MEB-1170 in rats and dogs have been described.[8][9] It has a longer duration than morphine in rodents.[3]
MEB-1170 was first described in the news media in 2017[4] and in the scientific literature in 2018.[3] It is being developed by Mebias Discovery.[1][10][4] As of April 2023, the drug is in phase 1 clinical trials for treatment of pain and opioid use disorder.[1][10] It is being developed for both prevention and treatment of opioid use disorder.[1][7][5] A phase 1 dose-ascending trial has been completed as of October 2024.[8] Mebias Discovery has received ongoing grant funding from the National Institute on Drug Abuse (NIDA) for the development of MEB-1170.[7][6][5] The chemical structure of MEB-1170 does not yet appear to have been disclosed.[1][3]